GEN Exclusives

More »

GEN Poll

More »
Dec 15, 2011

Second-Opinion Genetic Testing

In mid-January, the U.S. Patent & Trademark Office (USPTO) is expected to announce dates and places for hearings on confirming genetic diagnostic tests. USPTO faces a June 16 deadline for submitting to Congress a study on “effective ways to provide independent, confirming genetic diagnostic test activity where gene patents and exclusive licensing for primary genetic diagnostic tests exist.” Advocates for such testing say the current system based on patent eligibility drives up costs, limits patient options, reduces innovation, and harms medical practice. Developers of diagnostics, however, say patent eligibility provides the financial incentives that allow them to recoup the costs of developing the tests. Where does the truth lie?

Do you believe the U.S. can develop a system to protect innovator diagnostic firms but also safeguard those offering confirming tests against patent infringement?

Yes
 
  57.1%
No
 
  0.0%
Undecided
 
  42.9%

More Polls » View Results »

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?